Page 52 - วารสารกรมการแพทย์แผนไทยฯ ปีที่ 16 ฉบับที่ 3
P. 52
386
μ“√“ß∑’Ë 3 °“√ª√–‡¡‘πª√– ‘∑∏‘º≈¢Õßμ”√—∫¬“ N040 μàÕºŸâ‡¢â“√à«¡«‘®—¬‚§√ß°“√‡ª√’¬∫‡∑’¬∫°àÕπ·≈–À≈—ß√—∫ª√–∑“π
¬“ (n = 32)
μ—«™’È«—¥ª√– ‘∑∏‘º≈ °àÕπ‰¥â√—∫¬“ À≈—߉¥â√—∫¬“ P-value
†
º≈‡≈◊Õ¥∑“ßÀâÕߪؑ∫—μ‘°“√
§à“ CEA 5.02 ± 6.21 6.15 ± 8.68 0.152
§à“ CA-19-9 12.93 ± 11.96 17.89 ± 18.24 0.054
ª√–‡¡‘π§ÿ≥¿“æ™’«‘μ¥â«¬ T-FLIC 2 ‡
§–·ππ§ÿ≥¿“æ™’«‘μ 49.59 ± 9.18 46.81 ± 11.39 0.068
‡
†
À¡“¬‡Àμÿ «‘‡§√“–Àå∑“ß ∂‘μ‘¥â«¬ repeated One-way ANOVA ·≈– «‘‡§√“–Àå∑“ß ∂‘μ‘¥â«¬ paired t-test
μ“√“ß∑’Ë 4 º≈°“√ª√–‡¡‘π°“√μÕ∫ πÕßμàÕμ”√—∫¬“ N040 „πºŸâ‡¢â“√à«¡«‘®—¬‚√§¡–‡√Áß√–¬–·æ√à°√–®“¬·≈–‰¡àμÕ∫
πÕßμàÕ°“√√—°…“¡“μ√∞“π À≈—ß√—∫ª√–∑“𬓠(n = 32)
À≈—߉¥â√—∫¬“®”π«π
ª√– ‘∑∏‘º≈
(√âÕ¬≈–)
º≈°“√ª√–‡¡‘πμ“¡ RECIST Criteria À≈—ß√—∫ª√–∑“𬓧√∫ 36 —ª¥“Àå (§π:√âÕ¬≈–)
Complete response 4 (12.50)
Partial response 12 (37.50)
Stable disease 4 (12.50)
Progression 8 (25.00)
Unevaluable for response (assessment incomplete) 4 (12.50)
∂“π¿“懡◊ËÕ§√∫ 12 ‡¥◊Õπ
¡’™’«‘μÕ¬Ÿà 20 (62.50)
‡ ’¬™’«‘μ 12 (37.50)
(Kaplan Meier Curve) „π§√—Èßπ’È à«π„À≠à¡’Õ“¬ÿ‡©≈’ˬ 53.31 ± 10.29 ªï ´÷Ëß
Õ¥§≈âÕß°—∫®“°√“¬ß“π∑“ß√–∫“¥«‘∑¬“¢Õß¡–‡√Áß
Õ¿‘ª√“¬º≈ [6]
„πª√–‡∑»‰∑¬©∫—∫ªï æ.». 2553 ∑’Ëæ∫«à“Õÿ∫—μ‘
°“√«‘®—¬π’È¡’«—μ∂ÿª√– ߧå‡æ◊ËÕ»÷°…“§«“¡
°“√≥å¢Õß¡–‡√Áߪ“°¡¥≈Ÿ° Ÿß ÿ¥„π™à«ßÕ“¬ÿ 50-55
ª≈Õ¥¿—¬·≈–º≈‡∫◊ÈÕßμâπ¢Õß°“√„™âμ”√—∫¬“ N040
ªï „π°“√»÷°…“π’Ȭ—ßæ∫«à“°“√„™â¬“ N040 „πºŸâªÉ«¬
„πºŸâªÉ«¬¡–‡√Áߪ“°¡¥≈Ÿ°√–¬–·æ√à°√–®“¬∑’ˉ¡à
¡–‡√Áߪ“°¡¥≈Ÿ°√–¬–·æ√à°√–®“¬ ¡’º≈°“√μÕ∫
μÕ∫ πÕßμàÕ°“√√—°…“¡“μ√∞“π ®“°º≈°“√»÷°…“
πÕßμ“¡ RECIST criteria √âÕ¬≈– 62.5 ‚¥¬
· ¥ß„Àâ‡ÀÁπ«à“ºŸâ‡¢â“√à«¡«‘®—¬∑’ˇ¢â“√à«¡‚§√ß°“√«‘®—¬
‡ªìπ°“√μÕ∫ πÕß·∫∫ partial response ¡“°∑’Ë ÿ¥
